Atara Biotherapeutics Inc (NAS:ATRA)
$ 0.605 0.0486 (8.73%) Market Cap: 72.85 Mil Enterprise Value: 76.99 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 35/100

Atara Biotherapeutics Inc ECTRIMS Conference Call Transcript

Sep 13, 2019 / 01:30PM GMT
Release Date Price: $15.16 (-2.70%)
Operator

Ladies and gentlemen, thank you for standing by and welcome to the Atara Biotherapeutics ECTRIMS Conference Call. (Operator Instructions) Please be advised that today's conference may be recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, John Craighead, Vice President of Investor Relations and Corporate Communications. Thank you. Please go ahead, sir.

John Craighead
Atara Biotherapeutics, Inc. - VP of IR & Corporate Communications

Thank you, operator. Good morning, and good afternoon, everyone, and welcome to the Atara ECTRIMS 2019 data conference call. Earlier this morning, we issued a press release reporting positive preliminary data from our ongoing Phase I trial of ATA188. This press release and the slides we will be presenting during this call, are available in the Investors & Media section of atarabio.com.

I'm joined on the call today by Dr. Pascal Touchon, President and Chief Executive Officer; Dr. AJ Joshi, Chief Medical Officer; also with us today is Dr. Lawrence Steinman,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot